These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28500232)

  • 1. NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.
    Godbersen C; Coupet TA; Huehls AM; Zhang T; Battles MB; Fisher JL; Ernstoff MS; Sentman CL
    Mol Cancer Ther; 2017 Jul; 16(7):1335-1346. PubMed ID: 28500232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies.
    Pfeifer Serrahima J; Schoenfeld K; Kühnel I; Harwardt J; Macarrón Palacios A; Prüfer M; Kolaric M; Oberoi P; Kolmar H; Wels WS
    Front Immunol; 2024; 15():1457887. PubMed ID: 39267747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
    André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
    Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
    Maccalli C; Scaramuzza S; Parmiani G
    Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
    Cerboni C; Ardolino M; Santoni A; Zingoni A
    Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity.
    Herault A; Mak J; de la Cruz-Chuh J; Dillon MA; Ellerman D; Go M; Cosino E; Clark R; Carson E; Yeung S; Pichery M; Gador M; Chiang EY; Wu J; Liang Y; Modrusan Z; Gampa G; Sudhamsu J; Kemball CC; Cheung V; Nguyen TTT; Seshasayee D; Piskol R; Totpal K; Yu SF; Lee G; Kozak KR; Spiess C; Walsh KB
    Cancer Immunol Immunother; 2024 Aug; 73(10):209. PubMed ID: 39112670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKG2D and Its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis.
    Legroux L; Moratalla AC; Laurent C; Deblois G; Verstraeten SL; Arbour N
    Front Immunol; 2019; 10():154. PubMed ID: 30787931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
    Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
    Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
    Zou Y; Luo W; Guo J; Luo Q; Deng M; Lu Z; Fang Y; Zhang CC
    Eur J Immunol; 2018 Oct; 48(10):1750-1763. PubMed ID: 30063799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells.
    Zhao Q; Pang J; Yan F; Jiang Y; Cui D; Liu J; Jing L; Li Y; Liu Z; Tao L; Zhao X; Diao A
    Protein Expr Purif; 2021 Feb; 178():105783. PubMed ID: 33122138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
    Whitman E; Barber A
    Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
    Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
    J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.